Pharmacotherapy

Objectives:

To review the efficacy and cardiovascular safety of GLP-1 agonist and SGLT2 inhibitors for the treatment of type 2 diabetes in obesity class1
To summarize the impact of anti-obesity medications on type 2 diabetes including the new generation of pharmacotherapy for obesity

Speaker

Dr. Marie-Philippe Morin, MD, FRCPC. ABOM

Spécialiste en médecine interne générale et bariatrique/Internist and bariatric physician
Cheffe de service de médecine interne générale/Chief of internal medicine division
Institut universitaire de cardiologie et de pneumologie de Québec

Dr Marie-Philippe Morin works as a General Internal Medicine Specialist and Bariatric Medicine Specialist and chief of the internal medicine division at the Quebec Heart and Lung Institute. She is also a researcher in the field of obesity and cardiometabolic risk factors affiliated to this Institute and is an Assistant Professor affiliated to Laval University. She completed her Doctorate in Medicine and her residency in General Internal Medicine at Laval University. In 2016, she achieved a one-year fellowship in bariatric medicine through the University of Ottawa at the Ottawa Hospital Bariatric Centre of Excellence and LEAF Weight Management Clinic. In 2018, she also got a diploma of the American Board of Obesity Medicine. Besides being speaker in many obesity conferences, Dr Morin is co-chair of the Canadian Association of Bariatric Physicians and Surgeons and she is one of the authors of the 2020 Obesity Canadian guidelines. She is also co-president of the bariatric committee at the Quebec health ministry.